![]() ending 2 h post-treatment) and every 30 min thereafter up to 6 h post-treatment. The time plot of results ( Figure 3) shows the mean 30 min VO 2 for the second 30 min period (i.e. Thus, there was no baseline VO 2, and in addition the results for the first 30 min settling-down period were discarded. In the next experiment, therefore, vehicle or sibutramine (10 mg kg −1, p.o.) was given 1 h before starting VO 2 measurements over the next 5 h (i.e. Extending the post-treatment VO 2 measurements much beyond 4 h means changing the absorbers for carbon dioxide and water in the respirometers (thus disturbing the animals), or starting the measurements later, after dosing the animals. The VO 2 response to 10 mg kg −1 sibutramine shown in Figure 2 suggested that VO 2 had yet to reach an established plateau by the end of 2 h. Thermogenic effect of sibutramine over 2–6 h Radiolabelled 2-deoxy-glucose was purchased from Amersham International. Sibutramine hydrochloride monohydrate (N-N-methylamine hydrochloride) and Metabolite 2 (BTS 54505 1-3-methylbutylamine hydrochloride), both supplied by Knoll Pharmaceuticals the β-adrenoceptor antagonists atenolol (β 1-adrenoceptor antagonist Zeneca Pharmaceuticals) and ICI 118551 (β 2-adrenoceptor antagonist 1 - 3 - - 2 - butanolhydrochloride Zeneca Pharmaceuticals) the β 3-adrenoceptor agonist BRL 35135 ( R*,R*-(±)-methyl - 4 - -propyl]-phenoxyacetate hydrobromide SmithKline Beecham) the long-acting ganglionic blocking agent chlorisondamine (Ciba-Geigy) the noradrenaline reuptake inhibitor nisoxetine (Research Biochemicals International) and the 5-HT reuptake inhibitor fluoxetine (Lilly). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |